Merck Acquires Terns Pharma, Bolstering Hematology Pipeline with Novel CML Candidate TERN-701
Summary
Merck has officially announced its acquisition of Terns Pharmaceuticals, Inc., a strategic move to expand its hematology pipeline. The acquisition specifically targets TERN-701, a novel candidate for Chronic Myeloid Leukemia (CML). This announcement confirms earlier reports from Reuters that Merck was in advanced talks to acquire Terns for approximately $6 billion. For a pharmaceutical giant like Merck, this acquisition is material, providing a new growth avenue and diversifying its future product portfolio, which is crucial given the anticipated revenue declines for Keytruda due to patent expiration and IRA price setting, as highlighted in its recent 10-K. Traders will now focus on the financial specifics of the deal and the development timeline for TERN-701.
At the time of this announcement, MRK was trading at $116.68 on NYSE in the Life Sciences sector, with a market capitalization of approximately $287.7B. The 52-week trading range was $73.31 to $125.14. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.